Jonathan Thompson, MD, MS | Authors

Jonathan Thompson, MD, MS, on AEs and Limitations Reported in the Phase 2 BGBC008 Study

February 15, 2021

The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.

Jonathan Thompson, MD, MS, on the Impact of the Phase 2 BGBC008 Study Results

February 08, 2021

The ongoing phase 2 BGBC008 trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI-refractory composite AXL-positive non–small cell lung cancer.